Clinical Trials Logo

Acute Coronary Syndromes clinical trials

View clinical trials related to Acute Coronary Syndromes.

Filter by:

NCT ID: NCT06089343 Active, not recruiting - Clinical trials for Acute Coronary Syndromes

High-risk Features of Coronary Lesions in CTA and OCT

Start date: October 1, 2023
Phase:
Study type: Observational

This study is a multicenter and retrospective study. ACS patients who underwent CCTA or OCT from 1 months to 3 years prior to the event will be retrospectively identified. Plaques in the non-culprit vessels will be regarded as a primary control group.

NCT ID: NCT05999695 Enrolling by invitation - Clinical trials for Acute Coronary Syndromes

Self-management of Patients With Acute Coronary Syndromes

Start date: December 11, 2022
Phase: N/A
Study type: Interventional

Purpose : The purpose of this study is to investigate the tracking effect of selfmanagement programs on anxiety, depression, and quality of life in patients with Acute Coronary Syndromes (ACS).

NCT ID: NCT04937803 Active, not recruiting - Clinical trials for Coronary Artery Disease

Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)

DCB-ACS
Start date: April 19, 2021
Phase: N/A
Study type: Interventional

The DCB-ACS trial is a prospective, multi-center, non-inferiority, randomized controlled trail. The purpose of this trial is to evaluate the safety and efficacy of drug-coated balloon(DCB) in de novo lesions for acute coronary syndromes (ACS) .

NCT ID: NCT04714736 Completed - Clinical trials for Acute Coronary Syndromes

DyeVert System and Contrast-induced Acute Kidney Injury

REMEDIALIV
Start date: February 10, 2020
Phase: N/A
Study type: Interventional

The aim of the REnal Insufficiency Following Contrast MEDIA Administration TriaL IV (REMEDIAL IV) is to test whether the use of the DyeVert system is effective in reducing CI-AKI rate in ACS patients undergoing urgent/immediate (within 2 hours) invasive diagnostic and/or interventional cardiovascular procedures. The DyeVertâ„¢ system (Osprey Medical Inc., Minnetonka, MN, USA) is a novel device designed to reduce CM volume during coronary procedures, while maintaining fluoroscopic image quality. Patients with ACS scheduled for urgent/immediate coronary angiography/angioplasty will be enrolled and randomized into 2 groups: 1) DyeVert group (CM injection will be handled by the DyeVert TM system), and 2) Control group (CM injection will be carried out by a conventional manual injection syringe).

NCT ID: NCT04630288 Active, not recruiting - Clinical trials for Acute Coronary Syndromes

Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome

Start date: July 2, 2019
Phase:
Study type: Observational

Multicenter post-approval observational retrospective cohort study in routine clinical practice (Real World Evidence Study) to assess the 1-year safety profile associated with ticagrelor and clopidogrel therapy in a contemporary reprospective cohort of patients who survived the initial 30-day period after the index hospitalization for acute coronary syndrome (ACS).

NCT ID: NCT04241601 Recruiting - Clinical trials for Acute Coronary Syndromes

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY

IVORY
Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

Acute coronary syndromes (ACS) result from coronary plaque(s) disruption, which initiates a thrombotic process leading to partial or complete obstruction of the vessel lumen with subsequent myocardial ischaemia and necrosis. The mainstay of treatment is currently focused on the re-establishment and maintenance of coronary artery patency using anti-platelets and anticoagulants with or without mechanical dilatation and stenting of the culprit artery. Despite important advances in management, ACS still carries a risk of substantial morbidity and mortality. The improved efficacy of novel anti-platelet and anticoagulant agents have been limited by increased risk of haemorrhagic events. Future breakthroughs in management are most likely to arise from targeting other relevant pathophysiological pathways. Particularly, the immune response which is an important process that has been neglected in the management of patients with ACS. In this trial the investigators investigate the efficacy of low dose IL-2 compared with placebo in patients with ACS.

NCT ID: NCT04023630 Not yet recruiting - Atrial Fibrillation Clinical Trials

DUAL Antithrombotic Therapy in Patients With AF and ACS

Start date: October 1, 2019
Phase: Phase 4
Study type: Interventional

The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the rates of death or ischemic event-including myocardial infarction, definite or probable stent thrombosis, stroke, or urgent revascularization.

NCT ID: NCT03347435 Terminated - Clinical trials for Acute Coronary Syndromes

Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes

PHARMCLO
Start date: June 2013
Phase: N/A
Study type: Interventional

The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndromes, and is therefore one of the most frequently prescribed drugs worldwide. Accumulating data suggest that the response to clopidogrel is characterised by significant inter-patient variability in the degree of platelet inhibition and the risk of cardiovascular events. Recent research findings have highlighted the role of genetic variations in determining antiplatelet response variability, and this has aroused interest in genotyping all thienopyridine-eligible patients in order to identify those who would be at increased risk of harm if treated with clopidogrel. This is a prospective, multicentre, randomised study enrolling consecutive patients hospitalised because of an ACS with or without ST-segment elevation. The patients are randomised to undergo or not tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis. The genotyping is done using a Q3 System (a compact platform that enables the classic laboratory analysis of DNA by means of real-time PCR). The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. The patients randomised to the pharmacogenomic arm receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables. The patients randomised to the standard treatment arm receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care (clinical algorithm alone). For each patient, a record is made of the occurrence of cardiovascular death, non-fatal MI, stroke, BARC-defined bleeding, and definite or probable stent thrombosis. The primary endpoint is the composite of death due to cardiovascular causes, non-fatal MI and stroke. The secondary endpoints is the occurrence of definite or probable stent thrombosis, and BARC-defined major bleeding events (types 3-5).

NCT ID: NCT03107806 Terminated - Hyperglycemia Clinical Trials

Monitoring Glucose Levels in Patients With Myocardial Infarction

COMGAMI
Start date: April 2013
Phase: N/A
Study type: Interventional

To evaluate the OptiScanner® for continuous glucose monitoring as a tool to optimize glucose levels in patients hospitalized for acute coronary syndromes

NCT ID: NCT02753023 Recruiting - Heart Failure Clinical Trials

Registry Of Acute meDical Emergencies in Brazil

ROAD-Brazil
Start date: May 2015
Phase:
Study type: Observational [Patient Registry]

Critical patients in emergency room are seriously situations that need quickly diagnosis and treatment. Different predictors of prognosis can be related with mortality and morbidity in-hospital and in long-term. In Brazil, this kind of registry is not available. The aim of the study is analysis and report data about critical patients in Emergency Departments over all country, showing demographic, clinical and prognosis data about that in Brazil.